Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

Dec 4, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

Nov 30, 2017

Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

Nov 16, 2017

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

Nov 8, 2017

Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

Nov 2, 2017

Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

Oct 11, 2017

Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

Sep 19, 2017

Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

Sep 18, 2017

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

Sep 14, 2017

Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study